What's hot

View all perspectives
      Ultrasound guided injections on cadavers improve rheumatology trainees ability to do
      #joint #injections

      17 trainees -a

      Janet Pope Janetbirdope

      9 months 3 weeks ago
      Ultrasound guided injections on cadavers improve rheumatology trainees ability to do #joint #injections 17 trainees -a couple of hrs of cadaver inj ▶️ joint injection confidence improved esp uncommon / difficult areas Elbow Ankle Wrist @RheumNow #ACR24 @ACRheum abst#1310 https://t.co/ZcER4s8QcR
      No Increase in Cardiovascular Events with JAK Inhibitors in IBD Patients

      UMKC researchers have compared the use of JAK

      Dr. John Cush RheumNow

      9 months 3 weeks ago
      No Increase in Cardiovascular Events with JAK Inhibitors in IBD Patients UMKC researchers have compared the use of JAK inhibitors versus tumor necrosis factor (TNF) blockers in inflammatory bowel disease (IBD) patients, but failed to see an increase in major adverse… https://t.co/IOzckJIfYf https://t.co/8S6FnffVLG
      TYK2/JAK1 in Dermato? Interesting pre-clinical study of brepocitinib... but we really just need clinical data

      Glad to

      Mike Putman EBRheum

      9 months 3 weeks ago
      TYK2/JAK1 in Dermato? Interesting pre-clinical study of brepocitinib... but we really just need clinical data Glad to see this is headed straight to a Phase 3! Hoping they allow IVIG: has been a problem with many/most/all? recent dermato studies #ACR24 @RheumNow Abstr#0882 https://t.co/KS8fTMBpPR
      Kharouf et al. Secondary biologic failure in PsA common - 36% over 5 years. Predictors - higher baseline SJC HR 1.39 and

      Richard Conway RichardPAConway

      9 months 3 weeks ago
      Kharouf et al. Secondary biologic failure in PsA common - 36% over 5 years. Predictors - higher baseline SJC HR 1.39 and PASI HR 1.14. TNFi did better, HR 0.40, esp golimumab - but ?this as often used as first bDMARD? @RheumNow #ACR24 Abstr#1455 https://t.co/ET0WX6tKMr https://t.co/iVcCkM0hu3
      In this large 🇦🇺 RA cohort, median time on treatment for upadacitinib was lot higher than other JAKi
      (28mo vs 17mo

      David Liew drdavidliew

      9 months 3 weeks ago
      In this large 🇦🇺 RA cohort, median time on treatment for upadacitinib was lot higher than other JAKi (28mo vs 17mo) Why? Patient selection, or a real difference between JAKi? Would really like more comparative effectiveness data between JAKi #ACR24 OPAL group ABST1370 @RheumNow https://t.co/OU2ayzqIc8
      Spicy network SRMA, 123pts w/JAK-TNF-PLBO

      TNF >> JAK w/respect to malignancy (expected) & better than PLBO (s

      Mike Putman EBRheum

      9 months 3 weeks ago
      Spicy network SRMA, 123pts w/JAK-TNF-PLBO TNF >> JAK w/respect to malignancy (expected) & better than PLBO (spicy!) JAK > PLBO for heme cancers (makes sense); no significant (but slight trend) toward PLBO > JAK for all cancer The debate continues #ACR24 @RheumNow Abstr#0989 https://t.co/tBnb02gyzF
      Brenac et al. Orbital MRI to distinguish GCA AOIN/CRO from non-arteritic. @RheumNow #ACR24 Abstr#1641 https://t.co/qIwa

      Richard Conway RichardPAConway

      9 months 3 weeks ago
      Brenac et al. Orbital MRI to distinguish GCA AOIN/CRO from non-arteritic. @RheumNow #ACR24 Abstr#1641 https://t.co/qIwaX3qp02 https://t.co/5CIZ0aV98Z
      Which RA patients are at increased risk of JAKi adverse events? Does disease activity matter?

      in the upadacitinib ph3 t

      David Liew drdavidliew

      9 months 3 weeks ago
      Which RA patients are at increased risk of JAKi adverse events? Does disease activity matter? in the upadacitinib ph3 trials, high disease activity pts had more: serious infections HZ MACE VTE Active RA is a massive contributor to many AEs in JAKi pts #ACR24 ABST1393 @RheumNow https://t.co/DlFf9Sfbja
      Koc et al. STAMP trial in PsA. Secukinumab+MTX+GC vs MTX+GC(+SSZ if needed). Both could go to TNF if needed. Secukinumab

      Richard Conway RichardPAConway

      9 months 3 weeks ago
      Koc et al. STAMP trial in PsA. Secukinumab+MTX+GC vs MTX+GC(+SSZ if needed). Both could go to TNF if needed. Secukinumab significantly better at week 12 but no longer at week 24. @RheumNow #ACR24 Abstr#1457 https://t.co/4TGSiUPebV https://t.co/eAANkYIpzy
      Harkins @DrTrishHarkins et al. PROs predict relapse in PMR. pVAS, HAQ health status, FACIT-F all positive predictors. I

      Richard Conway RichardPAConway

      9 months 3 weeks ago
      Harkins @DrTrishHarkins et al. PROs predict relapse in PMR. pVAS, HAQ health status, FACIT-F all positive predictors. Interestingly PHQ-9 negative predictor. @RheumNow #ACR24 Abstr#1238 https://t.co/kj4WgmI0oq https://t.co/xLDzRZvxoA
      Gottlieb et al. TYK2i Zasocitinib in PsA. 12 week phase 2 RCT. Skin responses and MDA all favour zasocitinib but maybe n

      Richard Conway RichardPAConway

      9 months 3 weeks ago
      Gottlieb et al. TYK2i Zasocitinib in PsA. 12 week phase 2 RCT. Skin responses and MDA all favour zasocitinib but maybe not fantastic? PASI75 46%, PASI90 37%, PASI100 26%. MDA in photo. @RheumNow #ACR24 Abstr#1477 https://t.co/iX5iriESV2 https://t.co/RkEmcAZ80x
      Zhang @jeffsparks et al. Even more evidence that MTX does not cause ILD, and in fact prevents ILD, in RA, OR 0.48 in met

      Richard Conway RichardPAConway

      9 months 3 weeks ago
      Zhang @jeffsparks et al. Even more evidence that MTX does not cause ILD, and in fact prevents ILD, in RA, OR 0.48 in meta-analysis. @RheumNow #ACR24 Abstr#1384 https://t.co/YvQnmmvNjF https://t.co/crYUwHahDb
      The idea of patient-initiated follow-up for RA is enticing:
      patient & physician time is already stretched
      minimize u

      David Liew drdavidliew

      9 months 3 weeks ago
      The idea of patient-initiated follow-up for RA is enticing: patient & physician time is already stretched minimize unnecessary visits/improve access but what actually needs to go into the design, to make it safe/workable? A: plenty. 🇨🇦 pilot underway #ACR24 ABST1041 @RheumNow https://t.co/03u4bhnQ0v
      STAR trial of GC w/d in RA LDA
      SEMIRA of GC w/d controlled RA on Toci

      Very slight disease activity increase, but higher

      Eric Dein ericdeinmd

      9 months 3 weeks ago
      STAR trial of GC w/d in RA LDA SEMIRA of GC w/d controlled RA on Toci Very slight disease activity increase, but higher flares No symptomatic adrenal insufficiency, but data of abnormal ACTH stim No good evidence of steroid w/d symptoms Beth Wallace @RheumNow #ACR24 https://t.co/j6UPWlVNIu
      Slick poster, but must be careful w/real world data. Big risk of confounding/channeling bias

      Pts with MACE risk (not al

      Mike Putman EBRheum

      9 months 3 weeks ago
      Slick poster, but must be careful w/real world data. Big risk of confounding/channeling bias Pts with MACE risk (not always well-characterized by ICD codes) also less likely to receive JAK & therefore less liekly to have subsequent MACE #ACR24 @RheumNow Abstr#1394 https://t.co/lilU0byJ1s
      How well do you know this week's rheumatology news?
      Take the rheumIQ quiz
      Take the RheumIQ Quiz

      Podcasts

      • ACR24 IL-17 Topic Panel Advancing Care with IL-17 Pathway Insights
      • ACR24 JAK TYK Topic Panel
      • RheumNow Day 1 Recap ACR Convergence 2024 Highlights

      Catch up on Conference Podcasts

      ×